Parkinson's disease is the second most common neurodegenerative disorder. It is characterised by a typical movement disorder that occurs in part because of the selective degeneration of the dopaminergic neurons of the substantia nigra pars compacta. Current treatment for the motor disorder of Parkinson's disease consists of dopaminergic medications, but these come with significant adverse effects, themselves an important part of the clinical course of Parkinson's disease, particularly in advanced stages. Therefore, treatment is needed that can restore dopaminergic tone in the striatum in a physiological and targeted manner to avert these side effects. A number of potential regenerative treatments have been developed with a view to achieving this. Following decades of optimisation and development of stem-cell-based treatments and viral gene delivery, clinical trials are on the horizon. For these treatments to be widely useful, they must be clinically effective, cost efficient and safe, and a number of practical aspects regarding storage and delivery of treatment must be optimised. Many barriers have been overcome, and the field of regenerative medicine for Parkinson's disease is now increasingly focussed on how these treatments will be delivered, demonstrating the significant progress that has been made and the optimism surrounding these approaches.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease [1] . It results in a typical movement disorder consisting of bradykinesia, rigidity, rest tremor and, as disease progresses, postural instability [1] . A number of non-motor features also occur, such as cognitive impairment and dementia, neuropsychiatric symptoms (e.g. depression and anxiety), fatigue, anosmia and rapid-eye movement (REM)-sleep behaviour disorder [2] . The natural course of PD is one of gradual progression, with functional decline occurring over years [3] .
The neuropathological hallmark of PD is the presence of Lewy bodies and Lewy neurites-intra-neuronal protein aggregates consisting largely of abnormal alpha-synuclein [4] . While the non-motor features of PD are due to neurodegeneration in the cerebral cortex and a number of brainstem nuclei, the movement disorder of PD primarily relates to the relatively selective degeneration of the neurons of the substantia nigra pars compacta [1, 5, 6] . These neurons produce the neurotransmitter dopamine and deliver it to the striatum, where it plays a crucial role in control of motor activity and some cognitive processes. Therefore, treatment of the motor features of PD involves restoration of dopamine activity in the striatum. However, current treatment options result in significant adverse effects that themselves constitute an important part of the illness experienced by the patient, particularly in the advanced stages of disease [1] . There is therefore much interest in the development of novel therapies that can restore dopamine activity without incurring these unwanted side effects. In this review, we discuss progress towards these therapies and their future prospects for the management of PD.
Rationale for Regenerative Approaches in Parkinson's Disease
Current treatment of PD motor features generally involves the use of dopaminergic drugs. Most commonly, this involves administration of the dopamine precursor, levodopa, in combination with a peripheral dopa-decarboxylase inhibitor to minimise peripheral side effects. Dopamine agonists or monoamine oxidase B inhibitors may be used in some patients, though the majority require levodopa therapy as disease progresses. In the initial stages of levodopa treatment, most patients experience significant improvement in motor problems and an improvement in function. However, with prolonged treatment, problematic adverse effects can have a significant impact on quality of life. These can include neuropsychiatric features such as hallucinations, thought to be due to delivery of dopamine to extra-striatal brain regions (off-target effects). Patients may also develop disabling levodopa-induced dyskinesias-continuous involuntary movements that may affect the limbs, trunk or face. These motor effects are thought to be due to the manner in which dopamine reaches the striatum following levodopa administration, which is continuous rather than in a physiological pulsatile fashion [7, 8] . Additionally, severe motor fluctuations may occur due to variations in the plasma concentration of levodopa and its transit across the blood-brain barrier [9] . Sudden 'off' spells can be particularly disabling. Therefore, dopamine needs to be delivered specifically to the striatum in a physiological manner that is not achievable with current pharmacological agents.
Cell Grafting for Parkinson's Disease
The movement disorder of PD largely results from a decline in the number and functional capacity of dopaminergic neurons in the substantia nigra. The onset of disease probably precedes the development of motor features by several years [2, 10, 11] , meaning that significant neuronal loss has already occurred by the time of diagnosis [12] . Restoration of a population of cells delivering dopamine to the striatum could theoretically allow for improvement in motor abnormalities without the development of the off-target and motor side effects associated with prolonged use of dopaminergic medication. A number of cell sources have been considered as potential options for grafting in PD. The first reports involved the grafting of autologous adrenal medullary cells (which release small amounts of dopamine) into the striatum [13, 14] . The initial positive results in these patients, despite only a short period of follow-up, led to a number of patients receiving this type of graft [15] [16] [17] [18] [19] [20] . However, it became clear that the recipients in fact experienced little clinical benefit, with a high incidence of psychiatric complications [21] . Furthermore, post-mortem study of these patients indicated the grafted cells had not survived [22] .
Around the same time, there was interest in using foetal midbrains, which contain the developing nigral dopaminergic neurons, derived from terminated pregnancies as an alternative source of dopaminergic cells. Results with the first two patients were disappointing [23] , but adjustments to the grafting procedure led to significant clinical benefits in a number of recipients, with some able to come off medication [24] [25] [26] [27] . At post mortem, these grafts were shown to have survived for over two decades [28] . This suggested that cell-based approaches could indeed be useful for treating the movement disorder of PD, at least in some patients. However, enthusiasm was dampened following two sham-surgery controlled trials of foetal tissue grafts, in which little clinical benefit was observed, with several recipients developing graft-induced dyskinesias [29, 30] . These trials had several design flaws but did highlight the need for the approach to be optimised, for example, in terms of the delivery method, the age and number of foetal midbrains used, the immunosuppressive regimen, and the identification of a suitable recipient population. After analysis of the outcomes of these foetal grafts, a further trial was set up in Europe using an optimised approach with the aim of showing that cell-based therapies for PD can be effective in appropriately selected patients (https ://clini caltr ials.gov/ct2/show/NCT01 89839 0). In total, 11 participants in this trial have now received grafts and are undergoing follow-up. However, even if the approach is proven effective, it will not be a feasible widespread treatment for PD, predominantly because the supply of foetal tissue is inadequate.
A number of other cell sources have been investigated for grafting in PD, including porcine midbrain tissue, autologous carotid body cells and retinal pigment epithelial (RPE) cells bound to microcarriers (Spheramine), with disappointing results (Fig. 1) [31] [32] [33] [34] . Carotid body cells were investigated as a means of delivering glial-derived neurotrophic factor (GDNF) to the striatum, which had appeared to be effective in animal models of PD [35] . However, clinical effects were modest in human trials [32, 33] . RPE cells release small amounts of levodopa so have been investigated as a source of cells that could replenish striatal dopamine.
However, a sham-surgery controlled phase II trial demonstrated no benefit [31] . These approaches therefore did not offer any advantages over the use of foetal tissue, with which experience was building by this time.
Stem Cell Treatments for Parkinson's Disease
Though the grafting trials produced mixed results, the significant clinical benefit observed in some of the recipients of human foetal ventral mesencephalon grafts offered proof of concept that dopamine cell-based therapies can be useful in PD. However, particularly given that PD is a common condition, a reliable source of dopaminergic cells is required for this approach to be widely useful-a condition that cannot be met by the unpredictable supply of foetal tissue. In contrast, this is potentially achievable through the use of stem cells to generate dopaminergic neural progenitor cells for grafting. Though other stem cell types have been purported as potential treatment options, two stem cell approaches in particular might offer an effective treatment for the dopaminergic deficits of PD: embryonic stem cell (ESC)-derived and induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cells (Fig. 2) [36] .
Human ESCs were first derived in 1998, opening up possibilities for the development of regenerative therapies for a number of conditions, including PD [37] . ESCs are pluripotent cells derived from the inner cell mass of the early blastocyst, harvested from surplus human embryos from in vitro fertilisation procedures [36] . However, the generation of authentic dopaminergic neurons or their precursors has been challenging, and progress has been slow. In particular, while ESCs clearly could produce cells expressing tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis) and that these could survive transplantation into rodents, the yield varied widely [38] [39] [40] [41] . Subsequent refinements of the differentiation protocols led to reports of ESC products that could not only survive grafting and integrate into the host but also produce a degree of functional recovery in pre-clinical models [38] [39] [40] [41] [42] . A retrospective analysis of over 500 ESC-derived neural progenitor grafts into rats sought to identify factors that determined favourable graft outcome [43] . This study found that a high content of tyrosine hydroxylase-positive cells were obtained in grafts enriched with neural progenitors expressing caudal midbrain markers, such as EN1 and CNPY1. However, the markers that had traditionally been used to signify dopaminergic fate (LMX1A, FOXA2 and OTX2) were found to be expressed not only in midbrain nigral progenitors but also in the rostral midbrain subthalamic neuron progenitors, explaining the heterogeneity in graft outcomes [43] . Exposure to FGF8b at the later stages of the reprogramming protocol resulted in a high purity of neuronal progenitors expressing markers of caudal midbrain patterning, which, when grafted, yielded a high level of dopaminergic neurons and functional recovery [43] . This unexpected development in understanding means it is now possible to generate ESC-derived neural progenitors that yield consistently high numbers of tyrosine hydroxylasepositive neurons, which could serve as the basis of a cellreplacement therapy.
In 2007, conversion of human somatic cells to pluripotent stem cells was first reported, offering an alternative renewable source of cells that could serve as the basis of a regenerative therapy for PD [44, 45] . These iPSCs can also be differentiated into dopaminergic neural progenitors through differentiation protocols similar to those used with ESCs, potentially offering an alternative source for a cell-based therapy for PD, as has been shown recently in a primate model [46, 47] .
Each of these stem cell approaches has its own merits and drawbacks. Generation of ESC lines results in destruction of a viable human embryo, which of course results in ethical issues, though in most cultures the use of embryonic tissue that would otherwise be discarded is probably more ethically favourable than the use of foetal tissue [48] . ESC-derived grafts would be allogeneic in nature so would require a period of immunosuppression and would carry the associated risk of infection, malignancy and other adverse effects. These ethical implications do not apply to iPSCs, and they can potentially be used to generate autologous grafts, derived from fibroblasts of the recipient, possibly circumventing the need for immunosuppressive treatment. However, heterogeneity in the response to a reprogramming protocol between individuals would mean that the cell product would vary between patients, with each product potentially being subject to regulatory approval and safety testing [36] . The more likely scenario is that investigators will need to prove that their reprogramming and differentiation processes are robust, yielding similar results for each patient, before an iPSC-derived product could be approved for clinical use. Generation of autologous iPSC-derived grafts is probably therefore prohibitively expensive for widespread use, at least in most current regulatory environments. Finally, with respect to autologous grafts, one should also consider the fact that the grafted cells will contain any PD genetic susceptibility factors carried by the patient, so may be at increased risk of themselves succumbing to PD pathology, a situation seen in some long-term surviving human foetal mesencephalon transplants [28] .
One proposed option is the generation of haplobanks, in which iPSC lines could be derived from a number of individuals with specific homozygous human leukocyte antigen (HLA) patterns to provide coverage of a whole population. While this is an appealing prospect, such coverage through a haplobank would still require generation of a large number of iPSC lines, all of which would be subject to safety testing and protocol optimisation and the associated costs [36, 49] . Additionally, grafts delivered from haplobanks would probably still warrant a period of immunosuppression, nullifying one of the main advantages of the iPSC approach over ESCs [36] . The use of haplobanks may not be a major advantage for transplantation into immune-privileged sites such as the brain, but they may confer a significant advantage in achieving transplantation of cell products to other organs.
Both iPSC-and ESC-derived grafts involve a theoretical risk of tumour formation, through graft overgrowth, aberrant differentiation of the grafted progenitors or the presence of residual pluripotent cells in the graft, as discussed further in Sect. 5. Though tumours formed in some of the early pre-clinical in vivo studies [40, 41, 50] , developments in differentiation protocols have allowed for generation of refined cell products in which there are no residual pluripotent cells, and, at least in animals, no tumour formation.
In addition, bone marrow-derived mesenchymal stem cells have been investigated as a potential therapeutic option for PD. Tyrosine hydroxylase-positive cells have been generated from mesenchymal stem cells [51] , but generation of midbrain dopaminergic neurons has not been achieved, so they are unlikely to be useful as a cell-replacement therapy for PD [52] . Alternatively, it has been suggested that these cells may convey a neuroprotective effect through paracrine and anti-inflammatory properties [53, 54] . An open-label trial in a small group of patients with PD demonstrated the short-term safety of the use of these cells, but clinical effectiveness could not be demonstrated [55] .
Gene-Delivery Therapies for Parkinson's Disease
An alternative approach towards a regenerative treatment for PD involves the use of viral vectors to deliver genes into the striatum. A number of virus-based gene-delivery therapies have now been investigated, some aiming to increase striatal dopamine [56] [57] [58] [59] , with potentially regenerative potential, and some aiming to convey a neuroprotective, potentially disease-modifying effect [60] . Two phase I trials have investigated the safety of adeno-associated virus (AAV) vectors delivering aromatic amino decarboxylase (AADC; the enzyme responsible for the conversion of levodopa to dopamine) into the putamina of patients with PD [56, 57] . Both of these trials reported improvements in clinical and imaging parameters at 6 months. These procedures were reported to be welltolerated, though 30% of the subjects in one of the trials developed intracranial haemorrhages along the injection tract [56] .
Following these initial trials, a phase I/II trial in France and the UK investigated the safety of a lentivirus gene therapy (ProSavin, Oxford Biomedica, UK) [58] . Lentiviruses have a capacity for a larger genetic cargo than do AAV vectors, meaning it was possible to deliver the genes encoding the other two rate-limiting enzymes in dopamine synthesis, tyrosine hydroxylase and cyclohydrolase-1, in addition to AADC. The treatment was generally well-tolerated, but 73% of recipients experienced an increase in on-medication dyskinesias in the first 12 months, which improved with a reduction in levodopa dose. All patients demonstrated a significant improvement in the off-medication Unified Parkinson's Disease Rating Scale (UPDRS) motor score at 6 months, with continued improvement over 48 months [58] .
As well as targeting the dopamine synthesis pathway, AAVs have been used to deliver other genes to patients with PD. A phase I trial in which the GDNF-like growth factor, neurturin, was delivered in an AAV vector demonstrated that this approach was well-tolerated [60] , though clinical outcomes in a follow-up sham-surgery controlled double-blind trial showed no benefit [61] . The glutamic acid decarboxylase gene has also been delivered using an AAV vector, with improvement in the UPDRS motor score being reported at 6 months compared with a sham-surgery group [62] , which persisted at 12 months [63] .
Requirements for a Regenerative Therapy
As discussed, the past few decades have seen significant progress towards a clinically useful regenerative therapy for PD. Some of the experimental techniques have shown initial promise in pre-clinical and early clinical trials but have failed to live up to expectations in larger studies. Others, such as foetal midbrain grafts, appear to be effective in appropriately selected patients but are not likely to be clinically useful for logistical and ethical reasons. A number of criteria must therefore be met before a regenerative therapy is to be useful.
First, any potential future regenerative therapy must produce significant clinical benefit in the patient. With the aforementioned cell-based treatments, this relies on delivery of an adequate number of dopaminergic neuron precursors into the striatum. The graft must have a high purity of dopaminergic cells and must receive signals from the host brain so that dopamine is released in a physiological manner. Grafted cells must extend axons across sufficient distances to innervate the recipient striatum. Additionally, the grafted cells must survive for years for the patient to gain maximal benefit during the course of their disease. This includes avoiding rejection from the host immune system and avoiding acquisition of pathology following grafting. Gene-delivery techniques must result in acquisition of dopamine-producing potential in a sufficient number of striatal cells to restore dopaminergic tone. As with potential cell-grafting therapies, the target cells of gene-delivery treatments must avoid acquisition of PD pathology, at least for a number of years, to provide significant clinical benefit. It is also important that these therapies do not result in significant extra-striatal dopamine release, in order to retain the theoretical advantage over levodopa therapy. Finally, the cell transplants must be free of a significant number of cells that could mediate adverse effects, such as the serotonergic neurons that may have been responsible for the graft-induced dyskinesias seen in some recipients of human foetal mesencephalon transplants [64, 65] .
The second important consideration with regard to the utility of future regenerative therapies is safety. These experimental treatments not only involve a neurosurgical procedure, which itself conveys risks of intracranial haemorrhage and infection as well as those associated with hospital admission, but are also associated with specific safety concerns that must be addressed before they approach the clinic. With regard to stem-cell-based treatments, the most significant concern is of potential tumour formation. Though tumour formation has not generally been seen in pre-clinical studies involving optimised reprogramming protocols, the risk of tumour formation after grafting into humans, in whom the graft will potentially be in situ for decades instead of the 1 or 2 years in a rodent or non-human primate, is unknown. Unpublished spike-in experiments in which pluripotent cells were intentionally included in the graft have shown that tumour formation from residual pluripotent cells occurs early and with high frequency, so one would perhaps expect that, if tumours are not observed over a 1-year period in a rodent, the risk of tumour formation from residual pluripotent cells would be non-existent.
In addition to the theoretical risk of tumour formation from residual stem cells, there is also potential for increased tumour risk due to acquisition of mutations in the grafted cells during cell culture, in which mutations that favour replication, or prevent apoptosis for example, provide a survival advantage over wild-type cells. For instance, it is clear that mutations in the tumour-suppressor molecule P53 occur during cell culture, albeit with low frequency [66] . The risk that this poses in terms of de novo tumour formation following grafting is unknown, particularly in view of the fact that mutations in these tumour-suppressor genes may require a second hit to herald neoplastic transformation. There is also doubt about the relevance of acquisition of oncogenic mutations that are associated with non-neuronal cancers, for example BRCA1 mutations, which are strongly associated with breast cancer but are not seen in intracranial tumours. A planned Japanese clinical trial of iPSC-derived RPE cell transplants for age-related macular degeneration was halted after identification of a cancer-associated mutation in the cell product of the second patient [67] . Though there was no evidence of tumour formation with this cell product in animals, the risk that it posed to the potential recipient was difficult to interpret [68] . In view of this significant uncertainty about the implications of finding genetic abnormalities, the ways in which upcoming clinical trials will screen for genetic aberrations in graft products varies, where some may perform whole-genome sequencing, some may test for specific oncogenic mutations and some may test for karyotype anomalies only [69] .
Delivery of genes using viral vectors is also associated with specific risks, and safety must be proven before the method can be adopted in the clinic. The use of integrating vectors such as lentiviruses and gammaretroviruses can lead to insertional mutagenesis, with risk of transformation in the transfected cell [70] . Given that lentivirus gene therapies such as ProSavin target post-mitotic cells, the risk of malignant transformation is thought to be low, with no evidence of insertional mutagenesis in pre-clinical studies [58] . Lentiviral vectors are of low immunogenicity, so the impact of an intracranial host inflammatory response against the virus or transfected cells is unlikely to be of clinical significance.
Third, any regenerative therapy must be ethically acceptable if it is to be employed widely [48] . While the use of foetal tissue is particularly ethically contentious, the potential future therapies discussed are generally considered to be less so and are probably acceptable to most societies. Therefore, ethical barriers are unlikely to be a considerable challenge, although issues still exist with the use of human ESC-derived products in some countries.
Additionally, for these regenerative therapies to be widely used, they will need to compete economically with current and other future treatments. In particular, these treatments will need to be comparable, in terms of both efficacy and cost, with deep-brain stimulation and levodopa intestinal gel (Duodopa), both of which target the motor features of PD while minimising motor adverse effects [71, 72] . Furthermore, trials of novel multimodal drugs such as safinamide have demonstrated positive effects on motor function, with no increase in dyskinesia, providing another potential alternative to the regenerative therapies discussed [73] . While the cost of future regenerative therapies will depend on as yet undetermined manufacturing and marketing influences, the ultimate cost is likely to be similar to that of levodopa therapy and deep-brain stimulation and less than the current cost of Duodopa treatment, given the highly efficient differentiation protocols that now exist for making midbrain dopamine neuroblasts.
Finally, a number of technical aspects must be addressed for any of these regenerative therapies to become widely useful. Procedures for freezing, storing and thawing cellbased and virus-based products must be optimised and robust and must not alter the properties of the treatment. Production of biological products must adhere to good manufacturing practice regulations, which may require adjustments to the neurosurgical theatres in which these treatments will be delivered. While many issues remain to be resolved, the focus of the field is now increasingly shifting towards answering questions about the practicalities of how these treatments can be delivered, which highlights the progress made over the past couple of decades.
Characteristics of Suitable Patient Populations for Regenerative Therapies
Clinical efficacy will depend on defining an appropriate patient population to target with regenerative therapies. It is becoming increasingly clear that PD encompasses a variety of clinical patterns, with some patients experiencing exclusively motor features and others being at high risk of developing cognitive decline and dementia [3] . Some patients may be more predisposed than others to the development of dyskinesias. The rate of functional decline differs considerably within the PD population. Regenerative therapies designed to increase striatal dopamine, and essentially replace the function of the nigral neurons that have already been lost, will theoretically be effective in patients whose predominant features are bradykinesia and rigidity. However, in patients with or at high risk of developing dementia, in whom the pathological correlate is more widespread Lewy body pathology and loss of extra-nigral neuronal populations [6] , replenishing striatal dopamine will have limited effect on their clinical features. Although clinical markers of dementia risk are emerging, including tau haplotype and performance on specific cognitive tasks, the success of regenerative therapies will partly be determined by the ability to accurately determine which patients are likely to benefit from these approaches [74] .
One of the safety issues that arose in the randomised clinical trials of human foetal mesencephalon grafting was the high incidence of disabling graft-induced dyskinesias [29, 30] . However, graft recipients with pre-existing druginduced dyskinesias were not excluded from these trials, and it is felt that appropriate selection of patients for future cell-based therapy trials, along with the use of cell products of increased purity and optimised grafting protocols, will circumvent this risk. However, exclusion of those with established pre-existing drug-induced dyskinesias will prevent the use of these approaches in a significant proportion of patients with PD, and further work will be necessary to determine the population in which regenerative therapies can be used safely. An increase in dyskinesias was also observed in the ProSavin trial, which highlights the need to determine the optimal approach for striatal dopamine delivery before these techniques are used widely [58] .
Future Perspectives
Since the first reports of the isolation and culturing of human ESCs two decades ago, progress towards a stem-cell-based therapy that could be trialled in PD has been steady. This has warranted extensive in vitro optimisation of reprogramming protocols as well as in vivo pre-clinical studies, which are ongoing. Many challenges have been overcome, including unexpected findings in neurodevelopmental biology, and the first in-human trials of stem cell-derived dopaminergic neuron precursors are now on the horizon.
Trials of ESC-derived dopaminergic neuron precursors are due to commence in the USA and in Europe over the next 2 years [64] . Additionally, a study of ESC-derived neural precursor cells, sponsored by the Chinese Academy of Sciences (https ://clini caltr ials.gov/ct2/show/NCT03 11963 6), is currently in the recruitment phase. In Japan, trials of allogenic iPSC-derived neurons and autologous iPSC-derived neurons are expected to commence next year [69] . These trials will provide feasibility and tolerability data for stem-cell-derived treatments and early data about their clinical effectiveness. A follow-up trial of ProSavin in which an optimised gene-therapy product is to be investigated, is also due to commence in 2018.
Viral-mediated direct conversion of somatic cells (e.g. fibroblasts) to generate induced neurons also offers a potential source of dopaminergic neurons that could serve as a platform for a cell-based treatment for PD. This is a relatively novel technique, first described in 2010, that has a potential advantage over stem-cell-based therapies in that there is no stem cell phase during reprogramming, theoretically reducing the risk of tumour formation [75] . However, it has not yet been possible to generate high purities of dopaminergic neurons, and the potential number of neurons produced is limited by the number of available somatic cells, which is in contrast to the renewable supply of neurons that can be derived from ESCs and iPSCs. Therefore, induced neurons do not currently offer a realistic approach to a useful cell-based therapy. One interesting concept associated with this direct conversion approach is the ability to generate dopaminergic neurons through in vivo reprogramming of host astrocytes [76] . While this technique is a long way from being thought of as a potential therapeutic approach for PD, if safety can be demonstrated and pure dopaminergic neuronal yields can be achieved, it may be considered for further investigation in the future.
In addition to the experimental regenerative approaches discussed, there is also much interest in the development of therapies that could potentially slow or arrest disease progression. These putative treatments are designed to reduce the presence of aggregated alpha-synuclein, for example with novel immunological agents or repurposed drugs that enhance protein clearance mechanisms [77] . With a number of potential treatments currently in trials, the question is where will regenerative therapies fit into the future therapeutic approach to PD? While it is possible that these alpha-synuclein-reducing therapies may slow the progression of the motor and even the cognitive aspects of PD, they will not restore the function of neurons that have already been lost. Given that significant neuronal loss occurs before the clinical diagnosis of PD, even with disease-modifying treatments, many patients will still experience functional impairments due to the neuronal degeneration that occurs in the prodromal and pre-diagnosis stage of disease. The regenerative therapies discussed in this review aim to replace the function of the lost dopaminergic neurons, potentially restoring motor function to the pre-morbid level, without the problematic adverse effects seen with current dopaminergic drugs. One could therefore envisage a landscape in which regenerative therapies are used to restore motor function in patients who have already accrued motor disability, in combination with alpha-synuclein-reduction treatments to prevent disease progression, particularly in individuals at greater risk of cognitive symptoms.
Concluding Remarks
Since the early grafting trials for PD in the 1980s, significant progress has now been made towards effective and deliverable cell-based and gene-delivery therapies for the motor disorder of PD. Over the coming decade, these treatments will be investigated in the clinic, and it now seems likely that regenerative therapies will have a role in the management of PD in the medium-term future. Since the introduction of levodopa in the 1960s, significant advances in the treatment of PD have been few, but the regenerative approaches discussed in this review, in combination with the emerging potentially disease-modifying approaches, provide optimism for the future of regenerative treatments for PD.
